OPR - Delayed Quote • USD VRTX Jun 2026 400.000 call (VRTX260618C00400000) Follow 105.82 0.00 (0.00%) At close: February 23 at 2:48 PM EST Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for VRTX260618C00400000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: VRTX Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades. Pioneer Institute study finds IRA discourages non-opioid drug innovation Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know 2 Fantastic Growth Stocks to Buy Right Now Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. Health Care Roundup: Market Talk Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
